Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Net Margin (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Net Margin data on record, last reported at 244.66% in Q4 2025.

  • For Q4 2025, Net Margin rose 35798.0% year-over-year to 244.66%; the TTM value through Dec 2025 reached 86.6%, up 10902.0%, while the annual FY2025 figure was 435.33%, 23971.0% down from the prior year.
  • Net Margin reached 244.66% in Q4 2025 per LCTX's latest filing, up from 92.91% in the prior quarter.
  • Across five years, Net Margin topped out at 244.66% in Q4 2025 and bottomed at 1382.81% in Q2 2021.
  • Average Net Margin over 5 years is 338.15%, with a median of 230.51% recorded in 2023.
  • Peak YoY movement for Net Margin: skyrocketed 126936bps in 2021, then crashed -37184bps in 2023.
  • A 5-year view of Net Margin shows it stood at 389.69% in 2021, then plummeted by -64bps to 638.75% in 2022, then soared by 64bps to 230.51% in 2023, then skyrocketed by 51bps to 113.32% in 2024, then skyrocketed by 316bps to 244.66% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 244.66% in Q4 2025, 92.91% in Q3 2025, and 698.95% in Q2 2025.